- In July 2024, AbbVie submitted regulatory applications to both the FDA and the European Medicines Agency for Rinvoq (upadacitinib), seeking approval to treat adult patients with giant cell arteritis (GCA). Rinvoq, a JAK inhibitor, is already approved for multiple indications, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and Crohn’s disease
- In March 2024, the FDA approved Tyenne (tocilizumab-aazg), the first biosimilar to Actemra (tocilizumab), for both intravenous (IV) and subcutaneous (SC) administration. Tyenne, an interleukin-6 (IL-6) receptor antagonist, is approved for the treatment of giant cell arteritis
